Maria Hurst Appointed Senior Vice President, Condo/Coop Werny Division of FirstService Residential New York

PR Newswire

NEW YORK, May 13, 2026 /PRNewswire/ — As part of its continued growth, FirstService Residential, New York’s leading property management company, has elevated Maria Hurst to the role of Senior Vice President of the Condo/Coop Werny Division. In her new role, Hurst will oversee a diverse and expansive portfolio of condominium and cooperative properties while providing executive leadership, operational oversight, and strategic guidance to the division’s robust property management teams.

Hurst previously served as Vice President within FirstService Residential’s New Development Group, where she led the performance of consultative and property management teams while managing a broad portfolio of new development properties. Her promotion reflects more than two decades of demonstrated leadership, deep operational expertise, and an unwavering commitment to service excellence.

“Maria is an exceptional leader whose operational discipline and dedication to clients have made a lasting impact on every team and property she has supported,” said Keith Werny, President, Condo/Coop Werny Division. “Her extensive experience with new development, luxury, and established residential properties makes her uniquely positioned to guide the Condo/Coop Werny Division forward.”

Hurst joined FirstService Residential in 2003 as an assistant property manager and quickly advanced through roles of increasing responsibility, including property manager, senior property manager, and managing director. Over the course of her career, she has successfully led numerous large–scale capital improvement projects, such as façade restorations, window and roof replacements, Local Law 11 compliance projects, and Local Law 87 energy audit and retro–commissioning initiatives.

A past recipient of FirstService Residential’s prestigious Star Award, Hurst is recognized for her outstanding performance, her mentorship, collaborative leadership style, and consistent ability to drive results for her teams and clients.

“I am honored to step into this new role and continue supporting our clients and associates across the division,” said Hurst. “I look forward to building on our strong foundation and ensuring we continue to deliver the highest level of service and operational excellence.”

About FirstService Residential

FirstService Residential is simplifying property management. Its hospitality-minded teams serve residential communities across the United States and Canada. The organization partners with boards, owners, and developers to enhance the value of every property and the life of every resident.

Leveraging unique expertise and scale, FirstService serves its clients with proven solutions and a service-first philosophy. Residents can count on 24/7 customer care and tailored lifestyle programming, amenity activation, and technology for their community’s specific needs. Market-leading programs with FirstService Financial, FirstService Energy, and special districts teams deliver additional levels of support.

Boards and developers select FirstService Residential to realize their vision and drive positive change for residents in the communities in their trusted care.

FirstService Residential is a subsidiary of FirstService Corporation (NASDAQ and TSX: FSV), a North American leader in providing essential property services to a wide range of residential and commercial clients.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/maria-hurst-appointed-senior-vice-president-condocoop-werny-division-of-firstservice-residential-new-york-302770497.html

SOURCE Firstservice Residential, Inc.

Richardson Electronics, Ltd. Announces Technology Partnership with Gotion to Deliver U.S.-Manufactured Battery Energy Storage Systems

Collaboration Expands Battery Energy Storage Solutions for Commercial, Industrial, and Utility-Scale Projects

LAFOX, Ill., May 13, 2026 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL) today announced a new technology partnership with Gotion Inc, a global manufacturer of advanced battery technologies, to bring large-scale battery energy storage systems (BESS) to the multi-billion dollar U.S. market. The collaboration brings together two Illinois-based companies, Richardson Electronics in LaFox, Illinois, and Gotion Illinois’ battery manufacturing facility in Manteno, Illinois, to meet the rapidly growing demand for energy storage across commercial and industrial (C&I) and utility-scale applications.

Through this partnership, Richardson Electronics and Gotion will introduce two advanced BESS platforms: a 760-kWh system designed for C&I energy storage applications and a 5 MWh system engineered to support large-scale utility deployments. These systems will support projects ranging from customized C&I installations to large-scale utility projects in the hundreds of megawatts.

Manufactured and assembled in Manteno, Illinois, the new battery energy storage solutions will help customers manage rising electricity costs while providing greater control over energy usage and improving grid resilience. The collaboration also aligns with the continued growth of battery storage in Illinois following the rollout of the Illinois Climate Resilience and Grid Advancement (CRGA) program, which provides rebates of up to $250 per kWh for standalone battery energy storage systems.

With battery storage at the center of Illinois’ clean energy strategy, Richardson Electronics is well-positioned to support the expansion of BESS projects throughout the state and across the United States. The initiative will target both large-scale utility projects and customized C&I installations, helping organizations reduce energy costs and improve operational flexibility.

“Richardson Electronics is excited to partner with Gotion as we expand our power management and energy storage solutions portfolio,” said Greg Peloquin, Executive Vice President and General Manager of Power & Microwave Technologies and Green Energy Solutions groups. “Gotion’s advanced battery technology combined with Richardson’s deep knowledge of the U.S. power market and global engineering support capabilities positions us well to bring reliable, high-performance battery energy storage solutions to customers across utility and commercial markets.”

Under the agreement, Gotion will provide advanced battery technology produced at Gotion’s Illinois manufacturing hub in Manteno, Illinois, while Richardson Electronics will leverage its extensive experience in the U.S. energy market to support commercialization, engineering integration, and go-to-market strategy.

“This partnership reflects Gotion’s long-term commitment to building a localized, resilient battery supply chain in the United States,” said Jacky Yu, VP of Sales, Gotion, Inc. “By combining our advanced battery technology with Richardson Electronics’ deep market expertise, we are enabling scalable, domestically supported energy storage solutions that meet the growing reliability, cost and performance needs of U.S. customers across commercial, industrial and utility segments.”

“Our collaboration in Illinois represents an important step in expanding U.S.-based manufacturing and deployment of energy storage systems, supporting grid modernization, energy independence, and economic development,” Mr. Yu added.


About Richardson Electronics, Ltd.

Richardson Electronics, Ltd. is a leading global manufacturer of engineered solutions, green energy products, power grid and microwave tubes and related consumables; power conversion and RF and microwave components; CT X-ray tubes; and customized display solutions. More than 50% of our products are manufactured in LaFox, Illinois, Marlborough, Massachusetts, or Donaueschingen, Germany, or by one of our manufacturing partners throughout the world. All our partners manufacture to our strict specifications and per our supplier code of conduct. We serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific and semiconductor markets. The Company’s strategy is to provide specialized technical expertise and “engineered solutions” based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics and aftermarket technical service and repair through its global infrastructure. More information is available at www.rell.com.

Richardson Electronics, Ltd. common stock trades on the NASDAQ Global Select Market under the ticker symbol RELL.


About Richardson Electronics – Green Energy Solutions

Richardson Electronics Green Energy Solutions combines our key technology partners and engineered solutions capabilities to design and manufacture key products for the fast-growing energy storage market and power management applications. As a designer, manufacturer, technology partner, and authorized distributor, GES’s strategy is to provide specialized technical expertise and engineered solutions using our core design engineering and manufacturing capabilities on a global basis. We provide solutions and add value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair—all through our existing global infrastructure. GES focuses on products for numerous green energy applications such as wind, solar, hydrogen, and electric vehicles and other power management applications that support green solutions such as synthetic diamond manufacturing. For more information, visit us at https://www.rell.com/greenenergysolutions/.


About Richardson Electronics – Power & Microwave Technologies

For over 75 years, Richardson Electronics has been your industry-leading global provider of engineered solutions, RF & microwave, and power products. The Power & Microwave Technologies group continues this legacy and complements it with new products from the world’s most innovative technology partners. Richardson Electronics’ Power & Microwave Technologies group focuses on what we do best: identify and design disruptive technologies, introduce new products on a global basis, develop solutions for our customers, and provide exceptional worldwide support. As a global company, we provide solutions and add value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair—all through our existing global infrastructure. More information is available at rellpower.com | relltubes.com | rellaser.com.


About Gotion Inc.

Gotion Inc. is focused on advancing next-generation battery technology and energy storage solutions for the North American market. The company supports the development and localization of battery manufacturing, system integration, and energy storage deployment across the United States. Gotion Inc. works with local partners across the energy ecosystem to deliver reliable, high-performance solutions that strengthen grid resilience and support the transition to a more secure and sustainable energy future. For more information, visit us at https://www.gotion.com/


About Gotion Illinois

Gotion Illinois is developing advanced battery manufacturing capabilities in Manteno, Illinois, supporting the production and assembly of battery energy storage systems for domestic applications. The facility is designed to serve growing demand for energy storage across commercial, industrial, and utility-scale markets, while contributing to local job creation and the expansion of a U.S.-based battery supply chain. For more information, visit us at https://gotionillinois.com/

Contact Information:
Scott DuBois
Director Business Development | BESS
Richardson Electronics – Power & Microwave Technologies
630.277.2105 | [email protected] | rell.com



BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications

MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland. The data highlight the functional and proteomic differences of extracellular vesicles (“EVs”), including exosomes, derived from multiple mesenchymal stem cell (“MSC”) sources.

Detailed in an oral presentation titled, “MSC Exosome Proteomics Reveal Source-Specific Therapeutic Applications,” the study demonstrates that EVs derived from distinct MSC sources, including umbilical cord, brown adipose tissue, and bone marrow, exhibit unique protein signatures and biological functions that may enable targeted therapeutic and commercial applications. The data were presented on May 6, 2026.

“These findings provide important insight into how we can tailor exosome-based formulations to achieve specific biological outcomes,” said Francisco Silva, Vice President of Research and Development at BioRestorative Therapies. “By identifying distinct functional signatures across different MSC-derived EVs, we are advancing our ability to develop targeted, next-generation regenerative solutions across both clinical and aesthetic applications.”

Proteomic and gene ontology analyses revealed several key functional pathways associated with specific MSC-derived EV populations:

  • Proliferation and regenerative signaling: Enrichment in RNA and mRNA metabolic processes supports cellular growth, tissue regeneration, and remodeling
  • Cell adhesion and immune modulation: Enhanced signaling related to cell-substrate adhesion, phosphorylation, and immune response regulation supports extracellular matrix remodeling, wound healing, and inflammation control
  • Epidermal differentiation and barrier formation: Enrichment in keratinization and cornification pathways supports skin barrier repair, scar modulation, and keratinocyte function

“Central to our strategy is the development of a fully integrated regenerative platform spanning manufacturing, clinical validation, and commercial execution,” said Lance Alstodt, BioRestorative Therapies Chief Executive Officer. “Exosomes and other extracellular vesicle-based biologics represent a foundational component of that platform, with applicability across both our therapeutic programs and our BioCosmeceutical portfolio. These findings extend our ability to more precisely align biological function with intended application, enabling a more structured and intentional approach to product development. As we integrate these capabilities with our commercial architecture and our clinical validation efforts, including work being advanced with key opinion leaders such as Dr. David J. Goldberg, we are building a platform designed to align biological performance, clinical outcomes, and scalable commercial applications across regenerative medicine and aesthetics.”

Collectively, these findings support the development of differentiated EV-based formulations tailored to specific applications within regenerative aesthetics and dermatology, providing a framework for aligning source-specific biological activity with targeted clinical and commercial use cases. The Company believes these functional insights have direct implications for its BioCosmeceutical platform, enabling the design of targeted product formulations across a range of aesthetic and dermatologic use cases, including:

  • Skin rejuvenation and anti-aging applications, leveraging regenerative signaling to support collagen production and epidermal renewal
  • Post-procedural recovery solutions, designed to accelerate healing and reduce inflammation following aesthetic treatments
  • Scar and wound repair formulations, supporting improved tissue remodeling and barrier restoration
  • Barrier repair and hydration therapies, aimed at improving skin integrity and reducing trans-epidermal water loss
  • Hair and scalp health applications, targeting follicle activation and regenerative signaling pathways

“This work represents an important step in advancing our BioCosmeceutical platform from a formulation-based approach to a more structured, biology-driven design framework,” said Crystal Romano, Head of Global Commercialization at BioRestorative Therapies. “By identifying source-specific functional profiles across MSC-derived extracellular vesicles, we are strengthening our ability to align biological mechanisms with targeted product concepts, clinical validation pathways, and commercial deployment strategies. This level of integration is central to how we are building a differentiated, scalable platform across regenerative aesthetics.”

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, the Company’s two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and it also operates a commercial BioCosmeceutical platform:

Disc/Spine Program (brtxDISC): BioRestorative’s lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The Company has commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The U.S. Food and Drug Administration (“FDA”) has granted Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

Metabolic Program (ThermoStem®): The Company is developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

BioCosmeceuticals: BioRestorative has developed a commercial BioCosmeceutical platform. Current commercial products are formulated and manufactured in the Company’s cGMP, ISO-7 certified clean room facility. Each product features a cell-based secretome enriched with exosomes, proteins, growth factors, peptides, and other carefully selected active ingredients. This proprietary biologic portfolio has been thoughtfully engineered to support skin health and longevity while addressing visible signs of aging and enhancing overall cosmetic performance. Moving forward, BioRestorative also intends to explore the potential of expanding its commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company’s latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof, and the Company undertakes no obligation to update such statements.

CONTACT:

Investors
CORE IR
[email protected]



Vishay Intertechnology PAR® and TRANSZORB® TVS Deliver Power Dissipation of 3000 W in New DFN6546A Package

Featuring a Low 0.88 mm Profile and Wettable Flanks, Unidirectional and Bidirectional Devices Save Space and Provide Excellent Clamping Capability Up to 137 V

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today introduced four series of unidirectional and bidirectional 3000 W PAR® and TRANSZORB® surface-mount transient voltage suppressors (TVS) in the new DFN6546A package with wettable flanks. Providing space-saving solutions for industrial and automotive applications, the Automotive Grade T3KNxxA and T3KNxxCA series devices are AEC-Q101 qualified and offer high temperature operation to +185 °C, while the 3KDFNxxA and 3KDFNxxCA series meet the LL15i Industrial Reliability Qualification.

The latest package in Vishay’s Power DFN family, the DFN6546A features a compact 6.5 mm x 4.6 mm footprint and an extremely low typical height of 0.88 mm, allowing the Vishay General Semiconductors TVS diodes released today to make more efficient use of PCB space. At the same time, the devices’ advanced construction and die placement technology allow for a higher copper content and larger chip sizes, resulting in significant performance increases. Footprint-compatible with the SMPC (TO-277A) package, the diodes offer twice the power dissipation with a 20 % lower profile. Compared to devices in the SMC (DO-214AB), they offer the same power dissipation while reducing volume by 76 %.

The TVS are designed to protect sensitive electronics against voltage transients induced by inductive load switching and lightning. Typical applications for the AEC-Q101 qualified T3KNxxA and T3KNxxCA PAR series include advanced driver assistance (ADAS), lidar, camera, infotainment, and sensor systems; DC/DC converters; battery management systems (BMS) and onboard chargers; electric power steering (EPS); traction inverters; central control units; and electrical motor drives. The industrial-qualified 3KDFNxxA and 3KDFNxxCA TRANSZORB series will be used in robot control boards, process / flow control instrumentation, automation systems, and generator start controllers; 60 kW energy storage systems; server power modules; consumer entertainment devices; and telecom and medical equipment.

For these applications, the diodes offer excellent clamping capability with maximum clamping voltages from 16.7 V to 33.2 V for the T3KNxxA and 3KDFNxxA, and 16.7 V to 137 V for the T3KNxxCA and 3KDFNxxCA. The wettable flanks of their DFN6546A package allow for automatic optical inspection (AOI), eliminating the need for an X-ray inspection. Ideal for automated placement, the devices offer a MSL moisture sensitivity level of 1, per J-STD-020, LF maximum peak of 260 °C. The components are RoHS-compliant and halogen-free, and their matte tin-plated leads meet the JESD 201 Class 2 whisker test.


Device Specification Table:

Series T3KNxxA 3KDFNxxA T3KNxxCA 3KDFNxxCA
Power dissipation (W) 3000
Breakdown voltage (V) 12 to 24 12 to 100
Stand-off voltage (V) 10.2 to 20.5 10.2 to 85.5
Max. clamping voltage (V) 16.7 to 33.2 16.7 to 137
TJ max. (°C) 185 175 185 175
Polarity Unidirectional Bidirectional
Circuit Configuration Single
AEC-Q101 Yes No Yes No


Samples and production quantities of the new 3000 W TVS in the DFN6546A package are available now, with lead times of 12 weeks.

Vishay manufactures one of the world’s largest portfolios of discrete semiconductors and passive electronic components that are essential to innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and medical markets. Serving customers worldwide, Vishay is The DNA of tech.® Vishay Intertechnology, Inc. is a Fortune 1000 Company listed on the NYSE (VSH). More on Vishay at www.Vishay.com.

The DNA of tech
® is a registered trademark of Vishay Intertechnology, Inc. TVS and PAR are registered trademarks of Vishay Intertechnology, Inc.

Vishay on Facebook:
http://www.facebook.com/VishayIntertechnology

Vishay Twitter feed:
http://twitter.com/vishayindust

Links to product datasheets:

http://www.vishay.com/ppg?98814  (3KDFN12A thru 3KDFN24A)
http://www.vishay.com/ppg?98818  (3KDFN12CA thru 3KDFN100CA)
http://www.vishay.com/ppg?98808  (T3KN12A thru T3KN24A)
http://www.vishay.com/ppg?98817  (T3KN12CA thru T3KN100CA)

Link to product photo:

https://www.flickr.com/photos/vishay/albums/72177720333433144

For more information please contact:

Vishay Intertechnology
Peter Henrici, +1 408 567-8400
[email protected]
 or
Redpines
Bob Decker, +1 415 409-0233
[email protected]



Grove Collaborative Releases 2025 Annual Sustainability Report, Advancing Leadership in Plastic Reduction and Human Health Standards

Grove Collaborative Releases 2025 Annual Sustainability Report, Advancing Leadership in Plastic Reduction and Human Health Standards

Company reduces plastic footprint for the third consecutive year, expands ingredient standards to more than 10,000 banned and restricted ingredients, and deepens its commitment to the intersection of human and environmental health

SAN FRANCISCO–(BUSINESS WIRE)–
Grove Collaborative Holdings, Inc. (NYSE: GROV) (“Grove” or “the Company”), the world’s first plastic neutral retailer, leading sustainable consumer products company, Certified B Corporation, and Public Benefit Corporation, today launched its Sustainability Report for 2025. The report delivers a comprehensive update on Grove’s progress across plastic reduction, ingredient safety, climate action, forest conservation, and equity and belonging — reflecting the Company’s deepening commitment to the intersection of human and environmental health, and its mission to transform the consumer products industry into a positive force for people and the planet.

“We are building a platform that brings together high standards, broad assortment, and operational efficiency to serve millions of households. As we grow, we will continue to raise the bar for product safety, expand our impact on plastic reduction, and earn the trust of customers who increasingly expect more from companies.”

— Jeff Yurcisin, CEO, Grove Collaborative

Key highlights from the 2025 Sustainability Report can be found below. To read the full report and its progress on commitments across Beyond Plastic™, Healthier Homes, Climate Action & Emissions, Forests & Fiber, and Equity & Belonging, please click here.

Go Beyond Plastic™

2025 marked Grove’s strongest year of plastic reduction, with the Company reducing its total plastic footprint to 1.52 million lbs. — a 41% reduction from the 2023 baseline — and achieving a new company-low plastic intensity of 0.90 lbs. per $100 of net revenue. Since 2020, Grove has surpassed 18.7 million lbs. of nature-bound plastic collected through rePurpose Global, while customers purchasing plastic-reducing products have helped avoid over 8.5 million lbs. of plastic to date.

  • Beyond Plastic™ Assortment: 76% of Grove Co. SKUs now qualify under the Beyond Plastic™ standard, with net revenue from 100% Plastic Free products reaching 32% for 2025 — up from 26% in 2024.
  • Packaging Innovation: Launched FSC-certified paperboard gabletop refill cartons for Grove Co. hand soap, dish soap, laundry detergent, and fabric softeners — a lower-carbon alternative to previous aluminum packaging — and introduced home-compostable toilet bowl cleaner pod packaging using FSC-certified paper pouch and cellulose film.

Grove also reduced third-party brand plastic intensity on Grove.com from 1.01 to 0.87 lbs. per $100 of net revenue from 2024 to 2025, demonstrating that Grove’s impact as a marketplace extends well beyond its own brand. In partnership with 5 Gyres, Grove’s Spring 2025 limited edition collection raised funds to advance microplastics research, reinforcing the Company’s view that plastic reduction is inseparable from human health.

Human and Environmental Health

Sustainability isn’t just about protecting the planet — it’s about protecting the people who call it home. In 2025, Grove expanded its Healthier Homes initiative, building what it believes to be the most comprehensive product vetting and curation standards in retail.

  • Ingredient Standards: Expanded Grove’s banned and restricted ingredient list to more than 10,000 ingredients — including over 3,000 outright banned — covering hormone disruptors, microplastics, skin sensitizers, and indoor air quality concerns, informed by leading EU safety frameworks.
  • Expanded Assortment: Grew the marketplace by more than 40%, adding 100+ brands across cleaning, personal care, and wellness, with 300+ vetted brands now spanning 80 categories — including over 750 vitamin and supplement products hand-picked by Grove Wellness Advisors.

More than 96% of customers report trusting Grove to provide safe, healthy products, and nearly 80% say shopping with Grove has changed their daily habits toward more sustainable choices.1 Grove also published a library of science-backed Healthier Home Guides — covering topics from microplastics to safer pest control and refillable systems — to help customers make more informed decisions for their families.

Climate Action & Emissions

Grove continues to advance against its science-based targets approved by SBTi, committing to reduce Scope 1 GHG emissions by 42% by 2030 and sourcing 100% renewable electricity annually.

  • Grove Impact Network: Launched a new program to help brands and suppliers on the Grove platform set and measure climate goals, beginning direct outreach with the Company’s largest suppliers to co-develop emissions reduction strategies.
  • Sustainable AI: Became one of the first companies in its industry to disclose and measure its AI-related carbon footprint in partnership with Gravity, an open-source methodology now available for broader industry adoption.

Additional Highlights

In 2025, Grove customers contributed to 25,914 trees planted, 13,327 acres of land conserved, and 354,782 lbs. of plastic collected through Environmental Impact Shop partners. The Company made $327,423 in 2025 charitable donations and continued prioritizing products from women, BIPOC, LGBTQ+, and veteran-owned or -founded businesses across its assortment.

About Grove Collaborative Holdings, Inc.

Grove Collaborative Holdings, Inc. (NYSE: GROV) is the one-stop online destination for everyday essentials that create a healthier home and planet. Everything Grove sells meets a higher standard — from health to sustainability and performance — so you get great value without compromising your values. As a B Corp and Public Benefit Corporation, every order is carbon neutral and supports plastic waste cleanup initiatives. Shopping with purpose starts at Grove.com.

1 March 2026 internal survey of 1,050 active Grove customers.

Investor Relations Contact

[email protected]

Media Relations Contact

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Environment Climate Change Packaging Environmental Health Chemicals/Plastics Sustainability Manufacturing Green Technology Forest Products Natural Resources

MEDIA:

Logo
Logo

Community Health Systems to Participate in 2026 RBC Capital Markets Global Healthcare Conference

Community Health Systems to Participate in 2026 RBC Capital Markets Global Healthcare Conference

FRANKLIN, Tenn.–(BUSINESS WIRE)–
Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the 2026 RBC Capital Markets Global Healthcare Conference to be held May 19-20, 2026, in New York.

The Company will host a fireside chat presentation on Wednesday, May 20, 2026, at 9 a.m. ET, 8 a.m. CT. The fireside chat presentation will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website, www.chs.net, and a replay will be available using that same link.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 33 distinct markets across 13 states. The Company’s subsidiaries own or lease 64 affiliated hospitals with more than 9,000 beds and operate more than 900 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.

Investor Contacts:

Kevin J. Hammons

Chief Executive Officer

615-465-7000

Anton Hie

Vice President – Investor Relations

(615) 465-7012

KEYWORDS: New York Tennessee United States North America

INDUSTRY KEYWORDS: Nursing Health Hospitals Practice Management Other Health Managed Care General Health

MEDIA:

Logo
Logo

DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences – Along with its Definitive Proxy Statement & WHITE Proxy Card – Urging Shareholders to Vote “FOR” DOMA’s Three Highly Qualified, Independent Board Candidates

PR Newswire

DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of the Board’s Duty of Care

Maintains the Company should remove its CEO and Explore a Strategic Sale of the Company Instead of Pursuing Risky Litigation

Asserts Pacira Will Continue its Value-Destroying Behavior Unless Changes are Made to the Board; DOMA’s Nominees Will Bring Relevant Expertise in Risk Management and Commitment to Stockholder Value to Realign the Board with Shareholders’ Interests and Creating Certainty in Outcomes Instead of Gambling with the Company’s Future

MIAMI, May 13, 2026 /PRNewswire/ — DOMA Perpetual Capital Management (“DOMA Perpetual”), which, together with its affiliates (collectively, “DOMA” or “we”), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) (“Pacira” or the “Company”), has today sent a letter to the Company’s stockholders outlining the rationale for urgently needed change in the composition of the Company’s Board of Directors (the “Board”) and emphasizing how DOMA’s independent, experienced and highly qualified nominees would bring genuine independence to the Company’s Board and support the much-needed maximization of stockholder value.

In its letter, DOMA Perpetual asserts Management and the Board continue to promote a risky strategy of “bet the farm” litigation that has already likely cost the Company more than a third of future EXPAREL revenues in a prior settlement. Pacira’s revenue growth remains weak and substantially below what Management promised in its 5×30 plan, while operating expenses and executive compensation have increased dramatically. Stock-based compensation has risen 38% over the last five years and the Board has moved from performance-based compensation to RSUs, guaranteeing Management multimillion-dollar compensation packages while shareholders have been taken to the cleaners. In the last two years, CEO Frank Lee made $28 million while the Company’s net income was negative $93 million; astoundingly, in this period, Mr. Lee made more money than all shareholders combined.

Pacira’s stock price has fallen approximately 54% over the last 10-year period, 62% over the last 5-year period, and 29% since Frank Lee took over as CEO(1).

Management and the Board seem willing to gamble with the Company’s future in risky IP battles, despite a bruising loss, leading to a costly settlement, just last year. EXPAREL is an “essential and mission-critical” asset. DOMA contends the Company’s unmet goals and shifting metrics in its 5×30 plan are proof that the CEO is grossly underperforming and that any future legal loss related to EXPAREL would jeopardize the future of the Company. DOMA believes Pacira’s board is gambling with shareholder money in its continued IP litigation and unproven, cash-burning 5×30 plan, and that Pacira’s current strategy is a house of cards built by a Board culture that evinces a complete failure of risk management. Shareholders should not have to lose it all to expose the Board’s gross negligence.

The letter and our other materials can be downloaded here

The full text of the letter follows:

Dear Fellow Pacira Biosciences, Inc. Shareholders,

We are writing to you as fellow investors in Pacira BioSciences, Inc. (PCRX) (“Pacira” or the “Company”), a drug manufacturer that is falling well short of its potential and is in urgent need of a new direction.

DOMA Perpetual Capital Management LLC, together with its affiliates (“DOMA”) currently beneficially owns approximately 7.5% of PCRX common shares. We believe that electing our three highly qualified and investor-focused nominees at the upcoming June 9, 2026 Annual Meeting is the best chance to preserve value for all shareholders. We urge you to support our nominees using the WHITE proxy card or voting instruction form included in the DOMA definitive proxy statement.

Pacira’s Board of Directors (the “Board”) requires immediate change. We at DOMA believe the Company’s current strategy is fundamentally broken and the Board and Management are misleading investors about the true risks the business faces. We view the Board’s failure to fully appreciate or fully acknowledge these risks as amounting to gross negligence and a breach of the Board’s duty of care. Compounding these failures are the Company’s continued underperformance under the leadership of CEO Frank Lee, alongside massive overspending with zero value creation for shareholders. The Board’s interests do not appear to be aligned with shareholders, despite a fiduciary duty to represent them. The Board cannot be allowed to continue to ignore risks, burn through cash and destroy value while the Company faces a very real existential threat. We are asking shareholders to vote for DOMA’s nominees to the Board: Eric de Armas, Christopher Dennis and Oliver Benton “Ben” Curtis III (collectively, the “DOMA Nominees”) in an effort to protect the business and push for genuine value creation.

The results are stark: the PCRX stock price has fallen approximately 54% over the last 10-year period, 62% over the last 5-year period, and 29% since Frank Lee took over as CEO.1 This is hardly a record of achievement, nor one that should be rewarded at the expense of the true owners of the Company, our fellow shareholders.

RISKS OUTWEIGH REWARDS

The Company’s unduly optimistic disclosures have the effect of misleading investors about the true nature of the risk to the business. EXPAREL accounts for approximately 80% of Pacira’s total revenue, and a significantly higher portion of its net income.2 The product represents an “essential and mission-critical” asset to the business, according to the Marchand v. Barnhill standard. This Delaware Supreme Court case laid the groundwork for finding a board of directors liable for breaching their fiduciary duty and underscored the directors’ duty to identify and address any risks that could potentially harm the company they serve, reinforcing effective risk management as a duty of all board members. We believe Pacira’s Board is possibly in breach of its fiduciary duty of care, as it continues to ignore the very real risk posed by its “bet the house” litigation strategy.

As Pacira faced its first legal battle over EXPAREL’s patents, the Company was extremely bullish on its odds of emerging triumphant. In the Q2 2024 earnings call, Anthony Molloy III, Pacira’s Chief Legal and Compliance Officer, said of the 495 Patent: “This is only the first patent being litigated. Three additional infringement lawsuits are underway for our 348, 574, 575 and 706 patents, and these patents are broader than the 495 patent. We also have other patents that are forthcoming, many of which will be listed in the Orange Books with expiration dates through January 2041. In order to become commercially successful, eVenus would have to overcome all of our patents.” Just a few days later, the Court ruled against Pacira with respect to the 495 patent, and Pacira quickly moved to settle with eVenus, a settlement in which Pacira gave up an incredibly substantial percentage of EXPAREL’s future revenues. Pursuant to the Settlement Agreement, Pacira agreed to allow eVenus, beginning in 2030, to manufacture and sell certain volume limited amounts of generic bupivacaine liposome injectable suspension in the United States, which will increase to over 30% of the total supply in 2033. These percentages are expected to approximately equal the percentage of revenue from EXPAREL that Pacira will lose due to this settlement.3

In discussing the patents being challenged, the Company continues to tout multiple patents, “families” of patents, and new patents being added to the Orange Book. The Company has not done enough to explain to shareholders that key product patents on EXPAREL have expired, rendering EXPAREL dangerously vulnerable to future threats, and additional lost market share, from manufacturers of generics. Many of the patents Pacira now relies on to protect EXPAREL are manufacturing or method-of-use patents which do confer some protection, but not the same level of rigorous protection provided by a full suite of existing product patents.4 Further, the “families” of patents and their “thicket strategy” are not impenetrable. Once a “parent” patent is deemed invalid, the rest of the family can fall with it.

We believe the Company continues to materially understate and downplay the significant risks posed by the introduction of new generic versions of EXPAREL and the resulting patent disputes (the “EXPAREL Patent Litigation”), thereby misleading investors as to the durability of EXPAREL’s revenue stream. The Company characterizes its recent litigation settlement as “favorable,” yet we find it difficult to reconcile that description with a settlement that resulted in an estimated 38% of the supply of bupivacaine liposome injectable suspension in the United States being supplied by a single generic manufacturer as of 2033, and an expected corresponding loss in revenue from EXPAREL.5 Moreover, while Management touts the listing of 21 Orange Book patents as a “significant evolution,” we cannot point to anything the Board has done to prevent the worst-case scenario. The Company’s own Form 10‑K discloses two ongoing patent infringement actions against generic manufacturers, each of whom contends that these Orange Book–listed patents are invalid and unenforceable.6 As such, EXPAREL Patent Litigation appears to be a persistent and unresolved overhang that threatens to materially impair the Company.

We believe that the Company has not been transparent with shareholders by doing enough to disclose that certain key product patents for EXPAREL have expired. We believe there is an argument of “prior art” which means that there could be a path for additional generics to enter the market. Pacira is now overly reliant on limited manufacturing patents and method patents. The Company’s highly touted “5×30 Plan” is premised on the flawed assumption that the new generic threats will not be successful. The Company has already lost a patent case that will cost the Company a substantial percentage of future annual revenue from EXPAREL.7 This product alone accounts for nearly 80% of the Company’s revenue. If there is another win by one of the two generic companies in litigation with the Company, the 5×30 plan will be entirely insufficient to rescue the Company.8 The entire value of the Company is at risk as another similar settlement could cost the company the majority of its revenue. This Board is willing to put shareholders at risk of losing everything. Our goal is to stop that. The hope of success in risky litigation is not a strategy that a Board or management team should rely on when deciding the fate of a company or the investment value of its shareholders.

The 5×30 plan offers shareholders little to no protection from an adverse ruling in future legal fights. Instead of trying to quickly diversify cash flows, the Board supported a plan based on developing new drugs which, even when they are identified, could take many years to create any cash flow, but before then will burn a not insignificant amount of cash. If the Company loses another patent lawsuit, it is unlikely there will be sufficient capital left to push any of the pipeline drugs through clinical trials. Moreover, the deals recently finalized by management have yet to demonstrate meaningful results. The recent J&J deal for ZILRETTA has yielded disappointing results, as the brand experienced a decline in sales revenue in 2025 despite premium pricing that a patented drug typically commands.9 It is a distinct possibility that a few years from now, the Company could lose its patent case against the generics, followed shortly by ZILRETTA’s patent expirations10. In just a few years, the Company could be facing an existential crisis. Allowing these risks to grow without attempting to mitigate or address them is, in our view, an absolute failure of the Board’s duty of care and makes the case that the Board has exhibited gross negligence.

Taken together, these risks underscore just how precarious the Company’s reliance on EXPAREL truly is. The Company has failed to diversify its portfolio as it chose to develop new potential drugs, speculating, instead of going for certainty of outcomes and cash flow, and the reality is that EXPAREL remains its core asset and primary driver of enterprise value. Indeed, it would likely take many years for any innovation or new product line to meaningfully offset this dependence. As a result, Pacira rests on a fragile foundation created by Management’s overreliance on EXPAREL and delayed diversification. This has created a house of cards which could collapse in the next few years, with adverse litigation outcomes or accelerated generic entry which could rapidly erode value, potentially well before 2030.

SIGNIFICANT UNDERPERFORMANCE

CEO Frank Lee was hired despite his previous leadership of an unprofitable enterprise that failed to deliver any shareholder value for its public shareholders.11 In Q1 2026, Mr. Lee avers the Company will continue “to execute our 5×30 strategy to drive durable revenue growth.” The notion that there is anything “durable” about what Mr. Lee forecasts is patently misleading. Looking at the metrics Management holds up to claim it is executing on its 5×30 strategy reveals shifting goalposts and an absolute lack of any meaningful growth or material value creation for shareholders. The metrics touted seem impressive at first glance, but a deeper review yields a clearer picture of just how poorly the Company is performing.

When Pacira launched the 5×30 plan in January of 2025, it promised shareholders double-digit compounded revenue growth.12 Instead, in 2025, total revenues increased by only 4%, while R&D spending increased 44% and SG&A increased 25%.13 With even a small amount of scrutiny, it is obvious that the “measurable operational progress across its five 5×30 pillars: patients served, product revenue, profitability, pipeline advancement and partnerships, building value and driving durable revenue growth into and beyond 2030” touted by management in the Proxy Statement are essentially meaningless to the business’s bottom line, and to stakeholders’ interests.

Management takes credit for serving 2.5 million patients in 202514, and serving patients is a noble goal, but the Company must also be able to make money from treating those patients. A publicly-traded, for profit business must also be focused on profitability and generating value for shareholders.

EXPAREL’s year-over-year volume growth of 6.2% in 202515 is yet another metric cited with no link to profitability – volume growth alone does not increase earnings per share nor free cash flow. The Company is under-delivering on its own stated goal of a double-digit compounded annual growth rate. Management has accomplished very little in terms of growth, focusing on “volume growth” instead of earnings and free cash flow growth.

The business’s “record-high 2025 GAAP and non-GAAP gross margins” are misleading and unhelpful for shareholders. The business can make as much gross profit as possible, but if it is spending too much money there is nothing left for shareholders, which is exactly what is happening here. The Company is ignoring the fact that if Pacira loses another patent case, whatever products are in the pipeline won’t matter, because there won’t be any money left to fund them.

Management claims that there was significant growth in its J&J partnerships, but they are measuring from a low point. The fact is that from Q1 2024 to Q1 2026, there has been minimal growth.16 This appears to be intentionally misleading – as Management first drove down the numbers, and now wants credit for bringing them back to where they started.

 The Company’s claim that “Pacira’s stock is up over 35% since the launch of the 5×30 strategy” is an insult to the intelligence of shareholders. The stock has risen 35% after falling close to 50% when the court ruled against it in the eVenus case, and the stock is still down nearly 30% from where it sat when Mr. Lee was named CEO. The stock currently sits at a price that is over 70% down from its all-time high.17 Shareholders haven’t seen a return in the last 10-year, 5-year, 3-year, 2-year or YTD periods, reflecting the market’s absolute lack of trust in management and the Board for allowing this gross mismanagement of the Company.

Meanwhile, Management and the Board continue to gamble with shareholders’ capital and enrich themselves. By linking compensation to revenue targets, the Board has incentivized aggressive spending at the expense of growth of earnings per share, free cash flow and return on equity. This is evidenced by a 91% surge in R&D and SG&A expenses alongside a 36% rise in stock-based compensation over the last five years—all while net income plummeted by 83%, effectively evaporating the majority of shareholder value over the last three years. In fact, the combined net income over the prior three-year period is negative $50.5 million.18 

The Board shifted Management incentives from performance-based options to Restricted Stock Units (RSUs) in 2024, which can retain value even if the stock price declines, subject to vesting and forfeiture conditions.19 This further misaligns Management with shareholder interests as well as creating further dilution to shareholders. The Board has repeatedly granted awards without shareholder approval under Nasdaq Listing Rule 5635(c)(4), which permits employment‑inducement awards subject to independent committee approval and prompt public disclosure. By relying on NASDAQ Listing Rule 5635(c)(4), the Board was able to approve a large equity award for Mr. Lee and has since continued to capitalize on this rule by consistently adding more shares to the Inducement Plan without shareholder vote. Since January 2025, Pacira has issued shares under this rule over ten times without shareholder approval.20 This has diluted shareholders while further enriching executives, despite no shareholder return.

While operational costs and executive pay have trended upward, the Company has failed to post a profit in the last two years. As shareholders saw zero return, executives and directors took home a total of $121 million.21 CEO Frank Lee has taken home tens of millions of dollars in annual pay – a figure that, during his tenure, exceeds the total net income generated for all shareholders combined. Management’s multi-million-dollar payouts stand in stark contrast to the experience of shareholders. The stock price tells the story: years of persistent underperformance and a complete lack of value creation. This is a business that is being eaten alive by the people charged with protecting it. 

BOARD COMPOSITION & LACK OF APPROPRIATE OVERSIGHT

The Company’s recent efforts to “refresh” and reshape the Board are an implicit admission that something is wrong. After years of sustained underperformance, the Company has moved to add and rotate directors only after facing significant stockholder pressure, yet still refuses to acknowledge the full scope of the problem, or to pursue the most direct, value-maximizing solution. By maintaining a staggered Board and stripping away the right to call special meetings, the Company is obstructing shareholder oversight and dodging accountability.

In our view, this is a pattern of half measures: the Company wants credit for “revamping” the Board, but it stops short of the decisive accountability Stockholders deserve—namely, a serious, independent review of strategic alternatives, including a sale of the Company. The Company’s incremental changes appear to be designed to relieve pressure without making the hard decisions necessary to protect and maximize Stockholder value.

Pacira’s Board is primarily comprised of physicians, researchers and biotech operators lacking diversification.22 There is a dearth of risk management expertise, which has been underscored by the Board allowing the Company to engage in high-risk patent litigation for the second time without any downside protection. The Company has already lost a legal battle which ended in a settlement that permanently impaired the EXPAREL product. The Board’s composition skews heavily toward R&D and clinical and medical backgrounds, which prioritize speculative innovation over risk management and disciplined capital allocation. Pacira’s Board possesses a single member who is a former CFO of a biotech firm, where they oversaw persistent net losses and cash burn. Further, the Board’s independence is compromised by its lucrative compensation – nearly 2x that of the average Board compensation of other publicly-traded mid-caps – which rewards presence over performance, creating a fundamental conflict of interest with shareholders.23

We are also concerned that the Company continues to renominate certain incumbent directors notwithstanding questions about whether they have demonstrated the level of engagement and accountability stockholders should expect. For example, we believe Governor Chris Christie, who makes frequent TV appearances to comment on politics, is creating a major political liability to the Company. Further, Governor Christie has not shown the commitment of time and attention that is required in a period of heightened risk and strategic urgency. Despite being the only current board member with a legal background, he appears to have gravely underestimated the legal risk the Company faces. We are likewise not persuaded by the Company’s efforts to explain away directors’ absences or limited participation at this crucial inflection point in the Company’s history. Compounding the issue, the Board continues to add individuals with clinical backgrounds, who lack essential risk management experience and any proven track record of driving profitability. 

Based on what we believe to be a reasonable assessment of the risks involved, the Company must urgently evaluate strategic alternatives for EXPAREL, including a potential strategic exit. The failure to meaningfully consider this option reflects a breakdown in strategy and Board oversight with respect to the Company’s most critical asset. Our DOMA Nominees will advocate for a value-maximizing strategic alternative, including a strategic exit, designed to deliver tangible and imminent returns to fellow shareholders.

Given these facts and circumstances, we believe that Pacira, if left unchecked, will continue its current value-destroying behavior unless representatives of the stockholders are seated on the Board.
We stockholders must act together to prevent further value destruction.

OUR HIGHLY QUALIFIED NOMINEES

We believe that the three DOMA Nominees, Eric de Armas, Christopher Dennis and Oliver Benton “Ben” Curtis III, are immensely qualified, have the relevant expertise and commitment to stockholder value to realign Pacira’s litigation strategy, compensation decisions and overall strategy – which must focus on decision-making that is in the best interests of the Company’s stockholders. DOMA’s Nominees have extensive experience in healthcare, finance, legal and regulatory matters, leadership, operations, strategy and corporate governance. This expertise would help to realign the Company’s decision-making with the best interests of the Stockholders and help realize the full potential of EXPAREL.

DOMA’s Nominees will bring fresh, independent perspectives and rigorous scrutiny to the Board’s actions and decision-making over the past several years, ensuring the right questions are asked and that proper controls are in place. Critically, our Nominees will pursue every option to serve the best interests of the Company and its stockholders, including a fundamental reassessment of the Company’s strategic direction and investigation into prior Board actions and decision-making. That reassessment will encompass a potential sale of the Company, which would provide stockholders with a certain pathway to value realization, rather than leaving them hostage to binary litigation outcomes and the implications of an unpredictable appellate timeline. The DOMA Nominees are committed to rescuing the Company from the perilous position in which the current Board has placed it and to ensuring that stockholder interests are finally put first.

Our action plan would involve removing the current CEO and appointing an Interim CEO to assist with the sales process. The DOMA Nominees would form a subcommittee on the Board to oversee a potential sales process and, at the conclusion of that process, would ensure that shareholders vote on any potential sale, rather than leaving the decision up to the Board.

The current Board cannot be trusted to put shareholders’ interests ahead of their own and they cannot be allowed to decide how the Company handles the risks it faces – risks the Company still refuses to fully acknowledge. We believe Pacira’s stakeholders should be the ones who decide what happens to the Company they own. The process for exploring a potential sale of the business must be fully transparent and the only way to ensure that transparency is to nominate Board members who are there to uphold their duty to shareholders.

WE STRONGLY RECOMMEND THAT YOU VOTE “FOR” THE ELECTION OF EACH OF THE DOMA NOMINEES ON THE WHITE PROXY CARD INCLUDED IN THE DOMA PROXY STATEMENT.

If you have questions or need assistance voting your shares, please contact our proxy solicitor, MacKenzie Partners, Inc. toll-free at 1-800-322-2885 or via email at

[email protected]

.

Sincerely,

DOMA Perpetual Capital Management LLC

Contact:
DOMA Perpetual Capital Management LLC
[email protected]

or

MacKenzie Partners, Inc.
Bob Marese
[email protected]

CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

DOMA Perpetual Capital Management LLC, a Delaware limited liability company (“DOMA”), together with the other participants named herein, have filed a definitive proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of director nominees at the 2026 annual meeting of stockholders of Pacira BioSciences, Inc., a Delaware corporation (the “Company”).

DOMA STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS ARE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

The participants in the proxy solicitation are DOMA, DOMA1 LLC, a Delaware limited liability company (“DOMA1”), DOMA Perpetual LO Equity Master Fund LP, an exempted limited partnership organized under the laws of the Cayman Islands (“DOMA LO Master”), DOMA Perpetual Partners GP LLC, a Delaware limited liability company (“DOMA GP”), DOMA2 LLC, a Delaware limited liability company (“DOMA2”), Reliability LLC, an investment holding company wholly-owned by the John Templeton Foundation (“JTF”), Pedro Escudero, Christopher Dennis, Oliver Benton Curtis and Eric de Armas.

As of the date hereof, DOMA LO Master directly beneficially owns 1,965,775 shares of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). As of the date hereof, JTF directly beneficially owns 812,019 shares of Common Stocki. As of the date hereof, Pedro Escudero directly beneficially owns 159,000 shares of Common Stock. As of the date hereof, Mr. de Armas directly beneficially owns 1,389 shares of Common Stock. As Investment Manager of DOMA LO Master and JTF, DOMA may be deemed to beneficially own the 2,777,794 shares of Common Stock beneficially owned by DOMA LO Master. As the managing member of DOMA, DOMA1 may be deemed to beneficially own the 2,777,794 shares of Common Stock beneficially owned by DOMA. As general partner of DOMA LO Master, DOMA GP may be deemed to beneficially own the 1,965,775 shares of Common Stock beneficially owned by DOMA LO Master. As the managing member of DOMA GP, DOMA2 may be deemed to beneficially own the 1,965,775 shares of Common Stock beneficially owned by DOMA GP. As Founder and Chief Investment Officer of DOMA and Managing Member of DOMA GP, DOMA1 and DOMA2, Mr. Escudero may be deemed to beneficially own the 2,777,794 shares of Common Stock beneficially owned by DOMA and DOMA GP in addition to the 159,000 shares of Common Stock directly beneficially owned by Mr. Escudero. As of the date hereof, neither Messrs. Dennis nor Curtis beneficially owns any shares of Common Stock.

Disclaimer

This press release and the attached letter have been prepared by DOMA. The views expressed herein reflect the opinions of DOMA and are based on publicly available information with respect to Pacira BioSciences, Inc. (“Pacira” or the “Company”). DOMA recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with DOMA’s conclusions. DOMA reserves the right to change or modify any such views or opinions at any time and for any reason and expressly disclaims any obligation to correct, update, or revise the information contained herein or to otherwise provide any additional materials.

For the avoidance of doubt, this press release was not produced by any person that is affiliated with Pacira, nor was its content endorsed by Pacira. This press release is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. One or more funds managed by DOMA currently beneficially own shares of the Company.

Some of the materials in this press release contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “potential,” “could,” “opportunity,” “estimate,” “plan,” “once again,” “achieve,” and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on DOMA’s current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of DOMA.

1 See Bloomberg Database, stock price as of as of May 11, 2026, at 1pm EST, Frank Lee start date January 2, 2024.
2 See e.g. See Pacira Biosciences, Form 10-K (filed Feb. 26, 2026), other Pacira BioSciences Company Filings.
3 See “Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL,” Press Release (Apr. 7, 2025).
4 See Pacira Biosciences, Form 10-K (filed Feb. 26, 2026) Risk Factors – Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection and all patents will eventually expire.
5 See “Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation” Press Release (Mar. 12, 2026).
6 See Pacira Biosciences, Form 10-K (filed Feb. 26, 2026), Note 20 to Notes to Consolidated Financial Statements, Paragraph IV Certification Notices.
7 See”BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL,” Press Release (Apr. 7, 2025) (“While the agreed-upon volume-limited percentages are confidential, they begin at a high-single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement.”).
8 See Pacira BioSciences Form 10-K (filed Feb. 26, 2026), Note 20 to Notes to Consolidated Financial Statements, Paragraph IV Certification Notices.
9 See Pacira BioSciences Form 10-K (filed Feb. 26, 2026), Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations, Net Product Sales.
10 See Pacira BioSciences Form 10-K (filed Feb. 26, 2026), Item 1 Business, Patents and Patent Applications.
11 See Bloomberg Database; Under Frank D. Lee’s tenure at Forma Therapeutics, the Company went public in 2020 at $20 a share. The stock price declined 34%, until the announcement of an acquisition by Novo Nordisk in September of 2022, to acquire the Company at $20 a share, leaving shareholders with no return.
12 See “Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization,” Press Release (Jan 10, 2025).
13 See Pacira BioSciences Form 10-K (filed Feb. 27, 2025).
14 See Pacira BioSciences Proxy Statement on Form DEF14A (filed Apr. 28, 2026).
15 See Pacira BioSciences Proxy Statement on Form DEF14A (filed Apr. 28, 2026).
16 See Pacira BioSciences Form 10-Q (filed May 7, 2024); Pacira BioSciences Form 10-Q (filed Apr. 30, 2026).
17 According to Bloomberg Database.
18 See the Company’s 10-K filed on February 26, 2026, Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations.
19 See Pacira BioSciences Proxy Statement on Form DEF14A (filed Apr. 29, 2025).
20 See Pacira BioSciences Press Releases (Apr. 8, 2026, Mar. 6, 2026, Feb. 9, 2026, Jan. 8, 2026, Dec. 3, 2025, Nov. 6, 2025, Oct. 3, 2025, Sep. 5, 2025, Aug. 5, 2025, Jul. 3, 2025, Jun. 5, 2025, May 8, 2025, Apr. 11, 2025, Mar. 6, 2025, Feb. 6, 2025, and Jan. 10, 2025.
21 See Pacira BioSciences Proxy Statement on Form DEF14A (filed Apr. 28, 2026).
22 See Pacira BioSciences Proxy Statement on Form DEF14A (filed Apr. 28, 2026).
23 See The BDO 600 2025 Study of Board Compensation Practices of 600 Mid-Market Public Companies.

i DOMA is acting as investment manager with respect to the shares beneficially owned by JTF, over which DOMA exercises discretionary investment and voting authority. JTF is not making or sponsoring the director nominations.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/doma-perpetual-issues–mails-letter-to-shareholders-of-pacira-biosciences–along-with-its-definitive-proxy-statement–white-proxy-card–urging-shareholders-to-vote-for-domas-three-highly-qualified-independent-board-candida-302771135.html

SOURCE DOMA Perpetual

GAMCO Global Gold, Natural Resources & Income Trust Declares Monthly Distributions of $0.03 Per Share

RYE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of GAMCO Global Gold, Natural Resources & Income Trust (NYSE American: GGN) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions. The Board of Trustees declared cash distributions of $0.03 per share for each of July, August, and September 2026. Based on current dynamics, the Fund may make distributions in excess of the Fund’s distributable earnings. It is currently expected that distributions to common shareholders in 2026 will primarily constitute a return of capital for tax purposes.

Distribution Month Record Date Payable Date Distribution Per Share
July July 17, 2026 July 24, 2026 $0.03
August August 17, 2026 August 24, 2026 $0.03
September September 16, 2026 September 23, 2026 $0.03
       

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

Because the Fund’s current monthly distributions are subject to modification by the Board of Trustees at any time and the Fund’s income will fluctuate, there can be no assurance that the Fund will pay distributions at a particular rate or frequency. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution.

Short-term capital gains, qualified dividend income, ordinary income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. There are no capital loss carryforwards for book purposes. Therefore the Fund, on a book basis, may be distributing short term gains generated from option premiums that will not be taxable in 2026 because of the capital loss carryforwards available on a tax basis. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

David Schachter

(914) 921-5057

The Fund’s NAV per share will fluctuate with changes in the market value of the Fund’s portfolio securities. Stocks are subject to market, economic, and business risks that cause their prices to fluctuate. Investors acquire shares of the Fund on a securities exchange at market value, which fluctuates according to the dynamics of supply and demand. When Fund shares are sold, they may be worth more or less than their original cost. Consequently, you can lose money by investing in the Fund.

Covered Call and Other Option Transaction Risks. There are several risks associated with writing covered calls and entering into other types of option transactions. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, resulting in a given transaction not achieving its objectives. In addition, a decision as to whether, when, and how to use covered call options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful because of market behavior or unexpected events. As a writer of a covered call option, the Fund forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the exercise price of the call option, but has retained the risk of loss should the price of the underlying security decline.

About The GAMCO Global Gold, Natural Resources & Income Trust

The GAMCO Global Gold, Natural Resources & Income Trust is a non-diversified, closed-end management investment company with $1.0 billion in total net assets whose primary investment objective is to provide a high level of current income. The Fund invests primarily in equity securities of gold and natural resources companies and intends to earn income primarily through a strategy of writing (selling) primarily covered call options on equity securities in its portfolio. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE American – GGN
CUSIP – 36465A109

Investor Relations Contact:
David Schachter
(914) 921-5057
[email protected]



Lincoln Foundation for Education Receives Nearly $250,000 in First‑Quarter Grants to Support Student Success

First quarter saw employer-sponsored program grants from Delta Dental, Matco Tools, The Gene Haas Foundation and more.

Parsippany, NJ, May 13, 2026 (GLOBE NEWSWIRE) — The Lincoln Foundation for Education Inc. (LiFE), a nonprofit 501(c)(3) organization, received nearly a quarter of a million dollars in first‑quarter donations from employers and partners including Matco Tools, Delta Dental, The Gene Haas Foundation, TechSource Tools, 7×24 Exchange’s Empire State Chapter, BrassCraft, and the Darren Drake Foundation. These contributions will fund scholarships and awards for new and current Lincoln Tech students nationwide.

Additional support from WM and 7×24 Exchange will benefit Lincoln’s Student Sensitivity Fund, which provides food assistance, transportation support, and help with essential school-related expenses.

“We are very grateful to our partners for supporting LiFE and helping Lincoln Tech students pursue in‑demand careers,” said Sheri D. Leach, President of LiFE. “Together, we’re helping meet the growing need for skilled professionals across the country. Together we are fueling futures and funding dreams.”

Funding Highlights:

  • $100,000 from Matco Tools for Automotive, Collision Repair, and Diesel students nationwide
  • $75,000 from Delta Dental for Dental Assistant students in Iselin, NJ
  • $15,000 from The Gene Haas Foundation for Advanced Manufacturing students in Mahwah, NJ
  • $15,000 from TechSource Tools supporting students across all programs
  • $15,000 from WM to help students manage unplanned expenses that can disrupt their education
  • $10,000 from 7×24 Exchange’s Empire State Chapter for scholarships and Student Sensitivity Fund support
  • $11,000 from BrassCraft for Computerized Manufacturing students in Grand Prairie, TX
  • Grant from the Darren Drake Foundation supporting multiple skilled trades programs in Mahwah, NJ

  
About The Lincoln Foundation for Education Inc.

The Lincoln Foundation for Education, Inc. (LiFE) has a mission to provide financial aid and assistance, grants, scholarships, and awards to those individuals pursuing post-secondary education in technical or vocational education at LTI and other similar institutions. The ultimate objective is to provide industry and community organizations, who wish to support both the growth of individuals and the development of a qualified workforce, the ability to contribute aid to promising students who do not have sufficient financial resources to attend or graduate from a post-secondary vocational institution in a timely manner with minimal educational debt.

LiFE sees higher education as a catalyst, an agent of change for individuals, families, communities, and local economies. We envision a community that recognizes the importance of educational attainment and assures positive outcomes are accessible to all regardless of economic circumstance.

For more information, visit lincolnfoundationedu.org.



Sheri D. Leach, VP Student Affordability
The Lincoln Foundation for Education, Inc.
(973) 766-9679
[email protected]

Leidos to build initial 3,000 low-cost containerized munitions through Department of War framework agreement

PR Newswire

RESTON, Va., May 13, 2026 /PRNewswire/ — America’s warfighters will receive an initial 3,000 Leidos (NYSE: LDOS) Low-Cost Containerized Munitions (LCCM) through a framework agreement with the Department of War that advances President Donald J. Trump and Secretary of War Pete Hegseth’s “Arsenal of Freedom” initiative.

The new cruise missile is expected to significantly enhance the country’s ground-launched combat capability, demonstrating Leidos’ ability to rapidly scale defense production and deliver decisive capabilities to the U.S. military.

Leidos will expand its workforce and enhance its facilities in Huntsville, Alabama, and McEwen, Tennessee, to produce the LCCM. Consistent with the DoW’s desire to utilize commercial products, development of Leidos’ LCCM is company-funded, leveraging the technologies in its AGM-190A Small Cruise Missile (SCM) program.

“We’re answering the Department of War’s call to revolutionize the procurement of critical capabilities at scale, with a focus on speed to operational capability,” said Leidos Chief Executive Officer Tom Bell. “This agreement reflects the department’s appreciation of Leidos’ defense tech prowess and their trust in our proven history in delivering advanced missile technologies.”

Leidos started LCCM work in December, reaching a conceptual design with the Pentagon that is capable of achieving all mission objectives. Full system design, development and test will result in production beginning in 2027.

At approximately twice the size of the AGM-190A, the LCCM offers increased mission effectiveness and fuel capacity to maximize range. Building on the Leidos Small Cruise Missile’s heritage, the LCCM leverages key design features including a modular airframe and a common Weapon Open Systems Architecture (WOSA) to enable rapid integration, upgrades and mission adaptability. The design also utilizes Leidos’ established supply chain and scalable production approach. 

While initially ground-launched, LCCM’s modular design could also support maritime platform integration and air-launched variants.

Leidos’ decision to fund development and expand its production capabilities reflects its commitment to advancing operational capabilities through its NorthStar 2030 strategy. 

Leidos is a proven leader in the design, development and integration of advanced missile systems, launchers and precision strike technologies for the U.S. military. In addition to the AGM-190A, Leidos is the prime contractor for the U.S. Army’s Enduring Shield (Indirect Fire Protection Capability) launcher and supports next-generation hypersonic strike capabilities through its work on the Common Hypersonic Glide Body. The company also delivers precision munitions integration and advanced guidance and sensor technologies that strengthen integrated air and missile defense architectures.

About Leidos

Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.leidos.com.  

Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended January 2, 2026, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

Media Contact:

Philip Carder
(571) 926-6698 
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-to-build-initial-3-000-low-cost-containerized-munitions-through-department-of-war-framework-agreement-302771115.html

SOURCE Leidos Holdings, Inc.